Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae454 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Ren Jing und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, South China Hospital of Shenzhen University, Shenzhen 518111, China. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Thyroid Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Context
Multikinase inhibitors (MKIs) improve the treatment of refractory thyroid cancer, including radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) and advanced medullary thyroid carcinoma (aMTC).
Objective
This study aims to compare the efficacy of MKIs in improving survival outcomes and safety. Data Sources Comprehensive database searches of MEDLINE via PubMed, EMBASE, and Cochrane were performed from inception to December 2023. Study Selection Three independent authors selected these studies. Randomized controlled trials that compared the use of a MKI to other MKIs or placebo were included. Data Extraction and Synthesis This review followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Risk of bias was analyzed using the Cochrane risk of bias 2 tool. Bayesian network meta-analysis was performed. Treatments were grouped into common nodes based on the type of MKI. Main Outcomes and Measures Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included objective response rate, disease control rate, clinical benefit rate, and adverse events.
Results
Cabozantinib 60 mg/day (CAB60) was associated with the highest prolonged PFS in RAIR-DTC patients, followed by lentivatinib 18 or 24 mg/day (LEN18 or LEN24), and apatinib. PFS was also improved in aMTC patients who received CAB 140 mg/day (CAB140), CAB60, or anlotinib. A significantly greater improvement on the performance of OS was seen in CAB60, LEN24, anlotinib, and sorafenib in RAIR-DTC patients, but in aMTC patients there were lack of statistical differences. Compared with the low-dose MKIs, high-dose MKIs such as CAB, LEN, and vandetanib increased the incidence of adverse events.
Conclusion
CAB60, LEN, and apatinib are promising topical MKIs with statistically significant primary outcomes in RAIR-DTC patients, while CAB and anlotinib are effective in prolonging PFS in aMTC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Thyroid Surgery, South China Hospital of Shenzhen University, Shenzhen 518111, China.
- Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medicine Ultrasound, School of Biomedical Engineering, Shenzhen University Medical…
- Respiratory Medicine, Shenzhen Pingle Orthopedic Hospital (Shenzhen Pingshan Traditional Chinese Medicine Hospital), Shenzhen 518118, China.
ORCID-Profile: Peng Huang, Shijian Yi
Zitieren
APA
Jing, R., Wu, N., Wu, Y., Zhang, Q., Liang, Q., Huang, P., & Yi, S. (2024). Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae454
Vancouver
Jing R, Wu N, Wu Y, Zhang Q, Liang Q, Huang P, et al. Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae454
BibTeX
@article{Jing2024,
author = {Jing, Ren and Wu, Nan and Wu, Yang and Zhang, Qian and Liang, Qiankun and Huang, Peng and Yi, Shijian},
title = {Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae454}
}
EUVIMED